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  Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous 
environmental  contaminants p r e s e n t  i n  a i r  a n d  f o o d .  
Among  PAHs,  benzo(a)pyrene(BaP),  phenanthrene  (PH) 
and pyrene (PY) are considered to be important for their 
toxicity or abundance. To investigate the changes of bio-
markers after PAH exposure, rats were treated with BaP 
(150 µg/kg) alone or with PH (4,300 µg/kg) and PY (2,700 
µg/kg) (BPP group) by oral gavage once per day for 30 
days. 7-ethoxyresorufin-O-deethylase activity in liver mi-
crosomal fraction was increased in only BaP groups. The 
highest  concentration  (34.5  ng/g)  of  BaP,  was  found  in 
muscle of rats  treated with BaP alone at 20 days of treat-
ment; it was  23.6 ng/g in BPP treated rats at 30 days of 
treatment. The highest PH concentration was 47.1 ng/g in 
muscle and 118.8 ng/g in fat, and for PY it was 29.7 ng/g in 
muscle  and  219.9  ng/g  in  fat,  in  BPP  groups.  In  urine, 
114-161 ng/ml 3-OH-PH was found, while PH was 41-69 
ng/ml  during  treatment.  201-263  ng/ml  1-OH-PY  was 
found, while PH was 9-17 ng/ml in urine. The level of PY, 
PH and their metabolites in urine was rapidly decreased 
after  withdrawal  of  treatment.  This  study  suggest  that  
1-OH-PY in urine is a sensitive biomarker for PAHs; it 
was  the  most  highly  detected  marker  among  the  three 
PAHs and their metabolites evaluated during the exposure 
period and for 14 days after withdrawal.
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Introduction 
  Polycyclic aromatic hydrocarbons (PAHs) are by-prod-
ucts from incomplete combustion or pyrolysis of organic 
materials containing carbon and hydrogen and are present 
as mixtures in air and food [41]. Some of the PAHs are clas-
sified as possible human carcinogens [18]. The low molec-
ular weight PAHs have been shown to induce immune sup-
pression, phototoxicity, neurological, and reproductive 
dysfunction in experimental animals [2,44,39]. Most of the 
PAHs are metabolized to hydroxylated compounds by the 
liver microsomal NADPH-dependent cytochrome P450 
monooxidase system, then they are excreted into the urine 
and feces [15,18].             
  The biotransformation and metabolic activation, of carci-
nogenic PAHs, take place primarily by the action of the 
CYP1 family of cytochrome P450 monooxygenase [42]. 
The cytochrome P450 enzyme CYP1A1 catalyzes the gen-
eration of the reactive metabolites from the PAHs, and the 
metabolites subsequently result in the formation of adducts 
with DNA and protein [26,33,37]. The induction of the 
CYP1A1 enzymes in the liver microsomal fraction has 
been used as a biomarker for toxicity screening for many 
chemicals in experimental animals [12,38,40] by measure-
ments of 7-ethoxyresorufin-O-deethylase (EROD) activity 
[35]. Benzo(a)pyrene (BaP) is the most potent carcinogen;  
it is embryo toxic and teratogenic in animals [18]. The level 
of BaP may be a good marker for carcinogenic PAH con-
tamination in an environmental sample [7,41]. BaP is me-
tabolized by the liver microsomal mixed function oxidase 
system to highly reactive compounds that can bind to spe-
cific target sites of DNA, which is of critical importance in 
the initiation of BaP-induced carcinogenesis [3,14]. 
  Phenanthrene (PH) and pyrene (PY) have been found at 
high levels in the air and in food [10,11,32,41]. The level of 
PY in the air was highly correlated with the total amount of 
airborne PAHs; it is composed of a large portion of high 
molecular weight PAHs in occupational and environ-
mental samples [5,22]. The 1-OH-pyrene in urine is repre-
sentative of pyrene and the total amount of PAHs in occu-
pational and dermal exposure in humans; it is a good in-
dicator of mutagenic activity in animal and human hepatic 
fractions [6,21]. The 3-OH-benzo(a)pyrene and 3-OH- 
phenanthrene compounds have been reported to be the 
most abundant metabolites after BaP and PH exposure, re-362    Hwan Goo Kang et al.
Table 1. Changes of relative liver weight by treatment with a vehicle, benzo(a)pyrene alone (BaP) or benzo(a)pyrene with pyrene and
phenanthrene (BPP)
(Liver weight / body weight, %)
Groups
Treatment (day) Withdrawal (day)
10 20 30 7 14 21
Vehicle
        BaP
        BPP
3.27 ± 0.14
3.50 ± 0.11
3.31 ± 0.06
2.96 ± 0.13
3.18 ± 0.24
3.13 ± 0.12
3.07 ± 0.10
3.03 ± 0.17
3.02 ± 0.04
3.27 ± 0.14
3.05 ± 0.30
2.96 ± 0.14
3.00 ± 0.29
3.10 ± 0.05
3.00 ± 0.14
2.95 ± 0.13
3.23 ± 0.15
3.14 ± 0.19
Chemicals were treated for 30 days via gavages to 9 week old female SD rats. Values are the mean ± SD (n = 3).
spectively, in human urine [16]. 
  To investigate the changes of biomarkers after exposure 
to PAHs, we administered BaP, PH and PY, representative 
chemicals of the PAHs, to female rats. We determined the 
concentration of BaP, PH and PY in muscle and fat, and 
their metabolites in urine; in addition, we studied the 
EROD activity in the liver and the DNA adducts of BaP in 
blood lymphocytes as well as the serum biochemical pa-
rameters in a time-dependent manner.
Materials and Methods
  The chemical BaP, PH, PY, β-glucuronidase, ethoxyr-
esorufin, NADPH, dimethylsulfoxide, and corn oil were 
purchased form Sigma-Aldrich (USA), and the 3-OH-ben-
zo(a)pyrene, 1-OH-pyrene, 3-OH-phenanthrene and Ben-
zo(a)pyrene-r-7,t-8,t-9,c-10-tetradyrotetrol(+/-) were pur-
chased from the Midwest Research Institute (USA).
Animals and housing
  Eight-week-old female Slc : SD rats (SLC, Japan) were 
provided with tap water and commercial diet ad libitum. 
The animal room was maintained at a temperature of 22 ± 
2
oC, relative humidity 50 ± 10% and a 12-h light/dark 
cycle. All animals were cared for in accordance with the 
guidelines established by the National Veterinary Research 
and Quarantine Service, Korea.
Experimental design
  BaP, PH and PY were dissolved in dimethylsulfoxide and 
further diluted with corn oil to the dose of BaP (150 µg/kg), 
PH (4,300 µg/kg) and PY (2,700 µg/kg). One group of rats 
was  treated with BaP alone and another with BaP with PH 
and PY simultaneously given by oral gavage once per day 
for 30 days at a volume of 2 ml/kg and maintained for an-
other three weeks  after withdrawal. Muscle, fat, blood, liv-
er and urine samples were collected every 10 days during 
treatment and every 7 days after withdrawal of the treat-
ment. Three rats were housed in a cage specially designed 
to collect the overnight urine.  The urine samples were kept 
at 򰠏80
oC until measurement.
Determination  of  7-ethoxyresorufin-O-deethylase 
(EROD) activity in liver
  Individual liver samples were homogenized in ice-cold 
solution (0.25 M sucrose, 0.1 M Tris-HCl, 1 mM EDTA, 
pH 7.4). The microsomal  fraction was separated by ultra-
centrifugation and the collected pellet was further dis-
solved  with 1 ml of 20% glycerol solution (pH 7.4) con-
taining 0.1 M Tris-HCl, 1 mM EDTA and 0.25 M sucrose. 
Liver microsomal EROD activity was assayed according 
to the method of Pohl and Fouts [35].
Determination  of  the  biochemical  parameters  in 
serum
  Alanine  aminotransferase  (ALT), aspirate aminotrans-
ferase (AST) and alkaline phosphatase (ALP) in serum 
were determined using a commercial kit (Bayer, Germany) 
and a blood chemical analyzer (Express 550 Ciba Corning, 
USA).
Determination  of  benzo(a)pyrene-r-7,t-8,t-9,c-10- 
tetradyrotetrol (+/򰠏) in blood lymphocytes 
  Blood lymphocyte DNA was isolated with a DNA iso-
lation kit (Roche Molecular Biochemicals, USA). Then 
100 µg of DNA was dissolved in 0.1 N HCl solution and in-
cubated at 97
oC for 30 min to hydrolyze the BaP-DNA 
adduct. After cooling to room temperature, methanol was 
added to obtain a 10% methanol solution. Benzo(a)pyr-
ene-r-7,t-8,t-9,c-10-tetradyrotetrol (+/򰠏) was separated with 
a SeP-Pak C18 cartridge (Waters, USA). The purified sam-
ples were analyzed with liquid chromatography according 
to the method of Islam et al. [19].
Determination of parent compounds in muscle and 
fat, and their metabolites in urine 
  For the determination of BaP, PH and PY, 3 g of muscle 
(0.3 g of fat) was homogenized with liquid nitrogen and ex-
tracted with 50 ml of hexane by sonication for 30 min. 
Homogenates were filtered through anhydrous sodium sul-Changes of biomarkers with oral exposure to benzo(a)pyrene, phenanthrene and pyrene in rats    363
Table 2. Serum biochemical values by treatment with a vehicle, benzo(a)pyrene alone (BaP) or benzo(a)pyrene with pyrene and phenan-
threne (BPP)
Groups
Treatment (day) Withdrawal (day)
10 20 30 7 14 21
ALT
(unit/l)
Vehicle
     BaP
     BPP
28.0 ± 5.9
  40.5 ± 15.0
  51.5 ± 19.8
  23.4 ± 1.9
  30.5 ± 3.1
  25.6 ± 1.7
  29.5 ± 2.4
  31.8 ± 1.8
  27.7 ± 2.3
  25.8 ± 4.0
  30.9 ± 1.9
  25.8 ± 2.1
  21.8 ± 2.1
  26.4 ± 1.1
  26.1 ± 2.8
  25.7 ± 0.5
  30.2 ± 3.0
  26.0 ± 0.5
AST
(unit/l)
Vehicle
     BaP
     BPP
60.7 ± 9.1
  75.9 ± 10.5
  80.5 ± 13.0
  67.6 ± 6.7
  83.2 ± 6.6
  71.8 ± 3.9
 80.5 ± 6.3
  80.0 ± 5.5
   78.7 ± 0.05
 64.0 ± 7.9
  72.9 ± 8.5
 57.1 ± 0.4
  58.2 ± 1.5
  68.7 ± 1.7
  62.5 ± 6.9
 68.1 ± 2.2
  69.7 ± 5.5
    61.7 ± 0.12
ALP
(unit/l)
Vehicle
     BaP
     BPP
158.7 ± 34.7
185.3 ± 29.9
150.0 ± 25.4
  154.3 ± 26.2
155.3 ± 9.8
  175.0 ± 31.9
135.3 ± 9.0
  182.0 ± 25.4
  143.5 ± 21.5
117.7 ± 7.8
131.7 ± 3.8
  125.0 ± 13.5
122.0 ± 8.0
126.0 ± 8.1
  107.0 ± 10.2
109.0 ± 5.0
132.0 ± 2.9
    152.0 ± 15.6*
Chemicals were treated for 30 days via gavages to 9 week old female SD rats. Values are the mean ± SD (n = 3). ALT: alanine aminotransferase,
AST: aspartate aminotransferase, ALP: alkaline phosphatase. *Significantly different from vehicle control at p ＜ 0.05.
Fig. 1. Change of body weight by treatment with a vehicle (4 
ml/kg BW), benzo(a)pyrene 150 µg/kg alone (BaP) and ben-
zo(a)pyrene with pyrene 1,700 µg/kg and phenanthrene 4,300 µg
/kg (BPP). The chemicals were used for treatment for 30 days via
gavage in 9-week-old female SD rats. Values are mean ± SD.
fate and concentrated to about 1 ml at 45
oC with a rotary 
evaporator. The concentrated solution was further purified 
using an activated Florisil cartridge (Silica cartridge for 
fat). The PAHs were eluted with 18 ml of hexane and di-
chloromethane (3 : 1, v/v) solution, and the eluate dried at 
45
oC, then dissolved with 1 ml of acetonitrile by soni-
cation. Next, 20 ul of filtered solution was analyzed using 
liquid chromatography with a fluorescence detector ac-
cording to the method of Chen et al. [9]. Analysis of the pa-
rent compound, and their metabolites in urine, was con-
ducted using the method of Jongeneelen et al. with mod-
ifications [21]. A 7 ml sample of 0.2 M sodium acetate buf-
fer (pH 5.0) was added into 5 ml of urine for acidification; 
then β-glucuronidase (13,200 unit) and sulfatase (220 unit) 
solution was added. The mixture was incubated with a 
shaking incubator (37
oC, 210 rpm) for 16 h. After cen-
trifugation (3,000 × g for 10 min), the supernatant was 
loaded onto an activated Sep-Pak C18 cartridge, washed 
with 5 ml of 40% methanol, eluted with 8 ml of acetoni-
trile, and 10 ml of hexane and dichloromethane (3 : 1, v/v). 
The final eluate was evaporated at 45
oC and dissolved with 
1 ml of acetonitrile.
Statistical analysis
  The body weight gain, organ weight, feed consumption, 
and blood chemistry parameters were analyzed by break 
down and  one-way ANOVA, followed by the Duncan test 
as a post-hoc comparison using a statistics program (Ver. 
5.5; StatSoft, USA).
Results
Body weight, organ weights and blood chemistry
  The treatment groups showed no significant difference in 
body weight and relative liver weight compared to those in 
the vehicle control group (Fig. 1 & Table 2). Rats exposed 
to BaP or BPP did not show significant changes in the ac-
tivity of ALT, AST and ALP. However, the ALP activity 
was increased by 21 days after the withdrawal of BPP com-
pared to the ALP in the vehicle control group (Table 2). 364    Hwan Goo Kang et al.
Fig. 2. Liver microsomal EROD activity at different time points
by treatment with a vehicle (4 ml/kg BW), benzo(a)pyrene 150 µg
/kg alone (BaP) and benzo(a)pyrene with pyrene 1,700 µg/kg and
phenanthrene 4,300 µg/kg (BPP). Values are mean ± SD. 
*Significantly different from vehicle control at p ＜ 0.05.
Fig. 3. Changes of PAHs in muscle at different time points by treatment with benzo(a)pyrene 150 µg/kg alone (BaP) and benzo(a)pyrene
with pyrene 1,700 µg/kg and phenanthrene 4,300 µg/kg (BPP). Values are mean ± SD. 
EROD activity in liver and BaP adduct in lympho-
cytes 
  EROD activity, a major enzyme of CYP1A1 in the liver 
microsomal fraction was significantly increased (p  ＜ 
0.05) only in rats exposed to 30 days of BaP alone. There 
were no significant differences in the time course of EROD 
activity during BPP treatment and during the withdrawal 
periods of BaP and BPP (Fig. 2). Benzo(a)pyrene-r-7, 
t-8,t-9,c-10-tetradyrotetrol (+/򰠏) was not detected in the 
blood lymphocytes of rats exposed to BaP alone or with PH 
and PY. 
Time-course changes of BaP, PH and PY in muscle 
and fat
  The highest mean amount of BaP in muscle was 34.4 ng/g 
in the BaP treated group; it was 23.6 ng/g in BPP treated 
rats, an amount achieved after 20 days of treatment in both 
groups. The BaP concentration in muscle showed no sig-
nificant difference in comparisons between both treatment 
groups (BaP and BPP). In addition, the amount of BaP in 
muscle rapidly decreased after withdrawal of the treat-
ment. 
  The highest mean amount of BaP in fat was 3.2 ng/g in the 
BaP treated group; this amount was obtained by 20 days of 
treatment. The highest mean amount of PH was 47.1 ng/g 
in muscle and 118.8 ng/g in fat; for PY it was 29.7 ng/g in 
muscle and 219.9 ng/g in fat, which was also achieved by 
20 days of treatment. Both compounds were rapidly re-
moved from the system after withdrawal of treatment 
(Figs. 3&4, Table 3)  
Time-course changes of BaP, PH and PY and their 
metabolites in urine
  The 3-OH-BaP compound, a major metabolite of BaP, 
was not detected in urine during treatment or after with-
drawal of treatment in both the BaP and BPP exposed 
groups. The 3-OH-PH compound is a major metabolite of 
PH; it was found in the ranges of 114-161 ng/ml and the 
highest concentrations were reached by 30 days of treat-
ment. The concentrations of the parent compound (PY) 
were 42-69 ng/ml with the highest concentration reached 
by 30 days of treatment. The 1-OH-PY compound, a major 
metabolite of PY, was found to be in the range of 201-263 
ng/ml and the highest concentration was achieved by 10 
days of treatment; the parent compound was in the range of Changes of biomarkers with oral exposure to benzo(a)pyrene, phenanthrene and pyrene in rats    365
Fig. 5. Changes of PAHs and their metabolites in urine at different time points by treatment with  benzo(a)pyrene 150 µg/kg alone (BaP)
and benzo(a)pyrene with pyrene 1,700 µg/kg and phenanthrene 4,300 µg/kg (BPP). Values are mean ± SD.
Fig. 4. Changes of PAHs in fat at different time points by treatment with benzo(a)pyrene 150 µg/kg alone (BaP) and benzo(a)pyrene 
with pyrene 1,700 µg/kg and phenanthrene 4,300 µg/kg (BPP). Values are mean ± SD.
9-17 ng/ml with the highest concentration reached by 30 
days of treatment. The amounts of PY, PH and their metab-
olites were rapidly eliminated from the system after the 
withdrawal of treatment (Fig. 5, Table 3).
Discussion
  The PAHs are a group of several hundred compounds that 
are present as a mixture in air and food. BaP is the most 
toxic among the PAHs and wzll known as a carcinogen in 
animals. The level of BaP in environmental samples is a 
good marker for carcinogenic PAH contamination [7].The 
correlation between BaP and the carcinogenic PAHs was 
reported to be 0.98 in food [24]. PH and PY are less toxic 
than BaP, but they are found in high levels in the air, animal 
feed and food compared to the other PAHs [9,30,32]. 
Therefore, in this study, BaP, PH and PY were selected as 
representative PAHs. We determined the treatment dose of 
BaP as 150 µg/kg/day based on the reference maximal ex-
posure amount in humans, which was 0.055 µg/kg/day 
[41] and multiplying the maximal margin factor by 3,000. 
The dosages of PH and PY were determined to be 4,300 µg/ 
kg/day and 2,700 µg/kg/day, respectively; these doses 
were chosen based on the mean contamination ratios of PH 
and PY to BaP in air, food and feed. 
  The metabolic activation of carcinogenic PAHs occurs 
primarily through the action of the CYP1A family P450 
monooxygenase; CYP1A1 acts mainly by the hydrox-
ylation of BaP [35]. The activity of CYP1A1 was meas-
ured using the EROD activity [8,35,40]. Although the 
EROD activity in rats exposed to BaP was increased about 
44.7 fold in another reported experiment [28], in this study 366    Hwan Goo Kang et al.
Table 3. Maximum mean level of benzo(a)pyrene, pyrene and phenanthrene in muscle, fat and urine and their  metabolites in the urine
of rats orally exposed to BaP or BPP for 30 days
Treatment group Parent compounds Urine Muscle Fat Metabolites Urine
BaP
BPP
BaP
BaP
PH
PY
ND
ND
69.0 (30)
17.6 (30)
  23.6 (20)*
34.5 (20)
47.1 (20)
29.7 (20)
    3.2 (30)
    1.3 (30)
118.8 (20)
219.9 (20)
3-OH-BaP
3-OH-BaP
     3-OH-PH
     1-OH-PY
ND
ND
161.6 (30)
263.0 (10)
*Data are maximum mean level (ppb) at date (day) when maximum level was found. BaP: benzo(a)pyrene, BPP: benzo(a)pyrene + phenan-
threne + pyrene.
ND: not detected.
the increase was three fold compared to the control with the 
treatment of BaP alone for 30 days. These differences may 
be caused by the treatment dose used. The dose of Moorthy 
et al. [28] was more 20 times higher than that used in the 
present study. This result is also supported by Nilsen et al. 
[29] who showed that mice exposed to 10 mg diesel ex-
hausts for 14 days caused no increase of EROD activity. 
The threshold dose for the induction of hepatic EROD ac-
tivity was reported to be about 300 µg/kg for 5 and 6 ring 
PAHs [37]. PH and PY did not change the EROD activity 
in H4IIE cells, while the cells were sensitive to BaP [4]. 
Willett et al. [42] reported that fluoranthene inhibited the 
BaP induced EROD activity in fish. In this study, EROD 
activity in rats exposed to BaP with PH and PY was not 
changed. However, it was increased in rats exposed to BaP 
alone. PAHs bind to aryl hydrocarbon receptors (AhR) in 
the liver and are further metabolized to a hydroxylated 
compound. The high carcinogenic potency of certain PAHs 
is correlated with the  Ah-receptor (AhR) affinity, and the 
induction of the CYP1A enzymes leading to increased 
rates of formation of reactive metabolites [40]. Therefore, 
PH and PY may interrupt BaP binding to AhR; however, 
scaled experiments with additional samples as well as in 
vitro studies are required for the characterization of the 
changes in CYP1A1 activity with BaP with other PAH 
chemicals. 
  DNA adducts of BaP in various organs have been studied 
as biomarkers for PAH exposure or toxicity. In addition, 
blood lymphocytes have been suggested to be useful bio-
logical targets for DNA adduct formation [19,34,36]. 
Benzo(a)pyrene-r-7,t-8,t-9,c-10-tetradyrotetrol (+/򰠏), one 
of the main DNA adducts of benzo(a)pyrene, was not de-
tected in the blood lymphocytes of rats exposed to BaP 
alone or to PH in our study. The detection limit for ben-
zo(a)pyrene-r-7,t-8,t-9,c-10-tetradyrotetrol (+/򰠏) was about 
2.5 pg, which is comparable to that reported by Alexan-
drov et al.[1]. The same metabolite was found as an albu-
min adduct in rats exposed to 100 mg BaP/kg for 3 days or-
ally [19] and 10 mg BaP/kg by intra-peritoneal injection 
[13]. Although the dose of BaP in this study was higher 
than the maximum exposure level in humans, the dose of 
BaP used in this study may not have been enough to induce 
EROD activity to form reactive metabolites to bind to 
DNA. Our data suggests that DNA adducts in blood lym-
phocytes may have been too low to be detected. Therefore, 
a more sensitive method is needed to analyze BaP-specific 
DNA adducts.
  BaP is known to be readily absorbed from the gastro-
intestinal tract in animals. By contrast, the pretreatment of 
BaP, for 7 days, inhibited the accumulation of BaP in the 
body fat [41]. PY in an aqueous suspension was poorly ab-
sorbed from the GI tract; the amount observed was highest 
in the peritoneal fat compared to the liver, kidney, lung, 
heart, testes, spleen, and brain [27,43]. Data from the pres-
ent study showed that the amount of PH and PY in fat also 
was higher than in muscle. However, BaP was higher in 
muscle than in fat. BaP, PH and PY were rapidly removed 
from muscle, consistent with other reports [27,43], show-
ing that the rate of clearance of the PAHs form organs was 
very rapid.   
  Some of the PAHs are quickly metabolized by phase 1 en-
zymes in the liver to a hydroxylated form and they are then 
mainly excreted in the urine. Metabolites of PH and PY, or 
other PAHs in body fluid, may be useful biomarkers for 
PAH exposure in humans and animals [16,17,21,25]. Urine 
samples can be obtained quickly and easily in animals and 
humans, and may provide a useful biological sample for 
the study of exposure and toxicological assessment for en-
vironmental contaminants. I-OH-PY, 3-OH-PH and 3-OH- 
BaP are the major hydroxylated metabolites for PY, PH and 
BaP, respectively, in humans and animals [16,20,25].   
Pyrene is a relatively large portion of the high molecular 
weight PAHs, and it is found at high levels in the diet; its 
metabolite,1-OH-PY, found in urine has been suggested to 
reflect the total PAH contamination and is an indicator of 
the mutagenic activity of the PAHs in animals [5,6,22]. In 
the human, the ratio of 1-OH-PY to 3-OH-BaP was re-
ported to be 200 times higher [16]. The 1-OH-PY in urine 
reflects a recent exposure while the PAH-adduct reflects a 
more persistent and long-time exposure [23,31]. In the Changes of biomarkers with oral exposure to benzo(a)pyrene, phenanthrene and pyrene in rats    367
present study, BaP and its metabolite, 3-OH-BaP, were not 
detected and the concentration of PH was five  times higher  
than PY, while 1-OH-PY was detected at a two fold higher 
level than 3-OH-PH in urine. Our data show that the 
amount of parent compound in tissue and urine are propor-
tional to the dose used for treatment. However, the level of 
the metabolites may not be directly related to the dose; that 
is, although the treatment dose of PH was 1.6 times higher 
than that of PY, the metabolites of PH were 0.61 times 
higher than that of PY. The 1-OH-PY and 3-OH-PH com-
pounds were rapidly excreted into the urine after the with-
drawal of treatment; they were not detected 14 days after 
withdrawal. 
    In conclusion, the results of this study suggest that 
1-OH-PY in urine may be a candidate biomarker for ex-
posure to PAHs. 
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